Loading stock data…
AXSM
$245.64+10.50 (+4.47%)
After Hours$245.50-0.14 (-0.06%)· Last close Jun 9
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Axsome Therapeutics, Inc. in the Healthcare sector is trading at $245.64. Wall Street consensus targets $270.28 (21 analysts), implying a +10.0% move over the next 12 months. The stock is currently near its 52-week high of $246.41, remaining 50.2% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +10.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$245.64
Potential Downside
0%
Whystock Fair Value$245.64
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus21 analysts
Mean target$270.28+10.0%
Range$200.00 – $328.81
Fundamentals
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextrometho...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-344.96%
Volume
Today's trading volume
870,329
Recent News
Axsome Therapeutics Readies Auvelity Alzheimer’s Agitation Launch, Expands CNS Pipeline
Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing to launch Auvelity in Alzheimer’s disease agitation this month while continuing to expand the drug’s use in major depressive disorder and advance a broad central nervous system pipeline. Speaking at a Jefferies fireside chat
Does SUNOSI Patent Peace And New Migraine Data Change The Bull Case For Axsome Therapeutics (AXSM)?
Axsome Therapeutics recently resolved all U.S. patent litigation related to its wake-promoting therapy SUNOSI, granting five companies rights to market generics starting in 2040, while also presenting new SYMBRAVO migraine data at the American Headache Society’s 68th Annual Meeting. This combination of long-dated intellectual property clarity for SUNOSI and fresh clinical evidence for SYMBRAVO reshapes how investors may view Axsome’s product durability and migraine franchise. We’ll now...
Why Is Mirum Pharmaceuticals (MIRM) Down 10.1% Since Last Earnings Report?
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?
Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Otsuka showcases kidney drug data; Pfizer cuts an AI deal
Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends and Axsome warded off generic competitors.